Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4588161 | 1.00 | HSD11B1 (0.41) | HSD11B1ESR2ESR1TNK2 | |
| SCHEMBL4589265 | 0.88 | HSD11B1 (0.40) | HSD11B1ESR2ESR1 | |
| SCHEMBL6227828 | 0.83 | HSD11B1 (0.41) | HSD11B1ESR2ESR1 | |
| SCHEMBL4588595 | 0.83 | HSD11B1 (0.41) | HSD11B1ESR2ESR1 | |
| SCHEMBL6227825 | 0.83 | HSD11B1 (0.41) | HSD11B1ESR2ESR1 | |
| SCHEMBL4588592 | 0.83 | HSD11B1 (0.41) | HSD11B1ESR2ESR1 | |
| SCHEMBL4587813 | 0.82 | HSD11B1 (0.44) | HSD11B1ESR2ESR1TNK2 | |
| SCHEMBL4587816 | 0.82 | HSD11B1 (0.44) | HSD11B1ESR2ESR1TNK2 | |
| SCHEMBL4588779 | 0.76 | HSD11B1 (0.65) | HSD11B1ESR2ESR1 | |
| SCHEMBL6536200 | 0.73 | ESR1 (0.46) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | disclosed |
| EP-1517914-B1 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1517914-A2 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | Schering Aktiengesellschaft (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003104253-A2 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESRRA, ESR2, ESR1 | HSD11B1 61/4885ESR2 2/4885ESR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.